NAV

Tilmicosin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tilmicosin
DrugBank Accession Number
DB11471
Background

Tilmicosin is a macrolide antibiotic. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia haemolytica.

Type
Small Molecule
Groups
Investigational, Vet approved
Structure
Similar Structures
Weight
Average: 869.147
Monoisotopic: 868.566040644
Chemical Formula
C46H80N2O13
Synonyms
  • Tilmicosin
External IDs
  • EL-870
  • EL870
  • LY-177370
  • LY177370

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Tilmicosin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Tilmicosin.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Tilmicosin.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Tilmicosin.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Tilmicosin is combined with Ambroxol.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Tilmicosin.
ArticaineThe risk or severity of methemoglobinemia can be increased when Tilmicosin is combined with Articaine.
AtorvastatinThe risk or severity of adverse effects can be increased when Tilmicosin is combined with Atorvastatin.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tilmicosin.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Tilmicosin is combined with Benzocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Tilmicosin phosphateSMH7U1S683137330-13-3NESIVXZOSKKUDP-ARVJLQODSA-N
International/Other Brands
Micotil

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / O-glycosyl compounds / Monosaccharides / Piperidines / Oxanes / 1,2-aminoalcohols / Amino acids and derivatives / Carboxylic acid esters / Cyclic ketones / Lactones
show 11 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Aldehyde / Aliphatic heteromonocyclic compound / Amine / Amino acid or derivatives / Aminoglycoside core / Azacycle / Carbonyl group
show 24 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
XL4103X2E3
CAS number
108050-54-0
InChI Key
JTSDBFGMPLKDCD-XVFHVFLVSA-N
InChI
InChI=1S/C46H80N2O13/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3/b15-14+,25-19+/t26-,27+,28-,29+,30-,31-,32+,33-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45+,46-/m1/s1
IUPAC Name
(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-7-{2-[(3R,5S)-3,5-dimethylpiperidin-1-yl]ethyl}-16-ethyl-4-hydroxy-15-({[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione
SMILES
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC

References

General References
  1. Mee JF, O'Farrell K: Tilmicosin and calf pneumonia. Vet Rec. 1991 May 11;128(19):460. [Article]
  2. McGuigan MA: Human exposures to tilmicosin (MICOTIL). Vet Hum Toxicol. 1994 Aug;36(4):306-8. [Article]
  3. Ziv G, Shem-Tov M, Glickman A, Winkler M, Saran A: Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther. 1995 Oct;18(5):340-5. [Article]
  4. Zhang Y, Jiang H, Jin X, Shen Z, Shen J, Fu C, Guo J: Residue depletion of tilmicosin in chicken tissues. J Agric Food Chem. 2004 May 5;52(9):2602-5. [Article]
  5. Authors unspecified: Industry guidance on the administration of tilmicosin. Vet Rec. 2006 Aug 5;159(6):163. [Article]
  6. Von Essen S, Spencer J, Hass B, List P, Seifert SA: Unintentional human exposure to tilmicosin (Micotil 300). J Toxicol Clin Toxicol. 2003;41(3):229-33. [Article]
  7. Fodor L, Varga J, Gallowitsch F, Horvath-Papp I, Miklos G, Lajcsak A, Harmath A: Treatment of calf pneumonia with tilmicosin. Acta Vet Hung. 1993;41(1-2):41-9. [Article]
  8. Schumann FJ, Janzen ED, McKinnon JJ: Prophylactic medication of feedlot calves with tilmicosin. Vet Rec. 1991 Mar 23;128(12):278-80. [Article]
  9. Day FG: The value of tilmicosin in production medicine. J Am Vet Med Assoc. 1996 Mar 1;208(5):655-6. [Article]
  10. Atef M, Abo el-Sooud K, Nahed E, Tawfik M: Elimination of tilmicosin in lactating ewes. Dtsch Tierarztl Wochenschr. 1999 Jul;106(7):291-4. [Article]
KEGG Drug
D02492
ChemSpider
4445656
RxNav
38278
ChEMBL
CHEMBL1908333
ZINC
ZINC000245204941
Wikipedia
Tilmicosin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderOral200 g/kg
Granule
SolutionOral25 %
PowderOral200 mg/g
PowderOral20 %
Solution, concentrate
PowderOral
PowderOral10 %
SolutionOral
PowderOral50 %
SolutionOral100 mg/mL
Injection, solution
PowderOral500 mg/g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0484 mg/mLALOGPS
logP3.34ALOGPS
logP4.19Chemaxon
logS-4.2ALOGPS
pKa (Strongest Acidic)12.55Chemaxon
pKa (Strongest Basic)10.16Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count14Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area186.15 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity232.21 m3·mol-1Chemaxon
Polarizability95.79 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at February 25, 2016 19:01 / Updated at April 20, 2021 00:38